Oncotelic Therapeutics, Inc. (OTCQB: OTLC) announced the launch of its artificial intelligence-powered good manufacturing practices (GMP) manufacturing services platform at the 2026 BIO International Convention in San Diego. The platform integrates the company's proprietary PDAOAI technology with advanced robotics from its collaboration with TechForce Robotics, aiming to help pharmaceutical, biotechnology, and advanced therapeutics companies modernize their manufacturing operations through AI-driven workflows, digital quality systems, and intelligent automation.
According to the press release, the platform supports electronic batch records, manufacturing documentation, GMP workflow digitization, quality and compliance functions, and process monitoring. Oncotelic will also showcase progress with its Deciparticle nanomedicine platform, including SAPU003, a clinical-stage intravenous everolimus program currently in a Phase 1b study. The full press release is available at https://ibn.fm/upnBW.
The importance of this announcement lies in the growing need for efficient and compliant manufacturing in the pharmaceutical industry. By combining AI and robotics, Oncotelic's platform addresses critical challenges such as reducing human error, accelerating production timelines, and ensuring regulatory compliance. This could significantly impact drug development by enabling faster scale-up of manufacturing processes, particularly for complex therapies like nanomedicines and biologics. For the industry, it represents a shift toward digitized, data-driven manufacturing that could lower costs and improve quality control.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products, targeting high-unmet-need cancers and rare pediatric indications. The company's CEO, Dr. Vuong Trieu, has filed over 500 patent applications and holds 75 issued U.S. patents. Oncotelic also owns 45% of GMP Bio, a joint venture advancing its own pipeline of drug candidates. The company develops PDAOAI, its proprietary AI platform for drug discovery, lab automation, and AI-assisted GMP manufacturing. Through Oncotelic's relationship with SAPU Bio, an OEB-5 sterile injectable cGMP manufacturing facility, PDAOAI underpins the platform and its joint development work with TechForce Robotics. More information is available at www.oncotelic.com.
TechForce Robotics, the operating brand of Nightfood Holdings, Inc., designs and deploys purpose-built robotics and automation solutions for service, hospitality, and pharmaceutical manufacturing applications, in partnership with global robotics and manufacturing leaders. Further details can be found at www.techforcerobotics.com.
This launch could have broad implications for the pharmaceutical supply chain, potentially reducing dependency on manual processes and enabling more agile manufacturing. For investors and industry observers, the platform's success may signal a new standard for GMP compliance and efficiency. The latest news and updates regarding OTLC are available in the company’s newsroom at https://ibn.fm/OTLC.
